Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Ossianix is a privately held biopharmaceutical company focused on the discovery and development of novel biopharmaceuticals for a variety of Central Nervous System (CNS) and other diseases. The company utilizes its proprietary VNAR phage display libraries and its versatile blood-brain barrier (BBB) transport platform to engineer next-generation biologics, including multi-specific antibodies. Ossianix aims to address significant unmet medical needs by delivering therapeutics across the BBB to treat complex neurological disorders.
Core R&D hub for developing VNAR-based biopharmaceuticals and blood-brain barrier transport technologies, and corporate management.
Located within the Stevenage Bioscience Catalyst, providing access to state-of-the-art laboratories, advanced scientific equipment, and a vibrant, collaborative biotech ecosystem.
Highly scientific, research-driven, and innovative, with a strong emphasis on collaboration, problem-solving, and the pursuit of breakthrough therapies.
The Stevenage HQ is central to Ossianix's research and development efforts, leveraging the UK's strong life sciences infrastructure and talent pool.
Ossianix operates primarily from its headquarters in the UK and its US office in Philadelphia. While its physical presence is concentrated in these key biotech hubs, its research and development efforts aim to address global health challenges, particularly in neurological diseases. The company engages in international collaborations and targets global markets for its innovative therapies.
Stevenage Bioscience Catalyst, Gunnels Wood Road
Stevenage
Hertfordshire
United Kingdom
Address: University City Science Center, 3711 Market Street, Suite 800, Philadelphia, PA 19104
To engage with the vibrant US biotech ecosystem, foster partnerships, and advance the development and commercialization of Ossianix's therapeutic pipeline in the North American market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ossianix' leadership includes:
Ossianix has been backed by several prominent investors over the years, including:
Ossianix strengthened its scientific leadership with the appointment of Andreas Loew, Ph.D., as Chief Scientific Officer in mid-2023. No major executive departures have been publicly announced in the last 12-18 months.
Discover the tools Ossianix uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ossianix likely uses a common corporate email format, often combining elements of an employee's name with the company domain.
[first_initial][last]@ossianix.com
Format
fwalsh@ossianix.com
Example
75%
Success rate
Business Wire • May 16, 2024
Ossianix entered into a research collaboration with Ovid Therapeutics to identify and develop novel biologics that can penetrate the central nervous system (CNS) by leveraging Ossianix's BBB-crossing platform and Ovid's expertise in rare neurological diseases....more
Business Wire • September 19, 2023
Ossianix presented promising preclinical data on its blood-brain barrier (BBB) delivery technology and pipeline programs at the World CNS Summit, highlighting its capabilities in delivering therapeutic antibodies to the brain....more
Ossianix Press Release • June 13, 2023
Ossianix announced the appointment of Andreas Loew, Ph.D., as its new Chief Scientific Officer (CSO). Dr. Loew brings extensive experience in antibody engineering and discovery of novel biotherapeutics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ossianix, are just a search away.